MicroRNA-Based Radiation Biodosimeter (MiRAD)

Information

  • Research Project
  • 8856484
  • ApplicationId
    8856484
  • Core Project Number
    R43AI108019
  • Full Project Number
    5R43AI108019-02
  • Serial Number
    108019
  • FOA Number
    PA-12-044
  • Sub Project Id
  • Project Start Date
    6/1/2014 - 10 years ago
  • Project End Date
    5/31/2017 - 7 years ago
  • Program Officer Name
    RIOS, CARMEN I.
  • Budget Start Date
    6/1/2015 - 9 years ago
  • Budget End Date
    5/31/2017 - 7 years ago
  • Fiscal Year
    2015
  • Support Year
    02
  • Suffix
  • Award Notice Date
    4/29/2015 - 9 years ago
Organizations

MicroRNA-Based Radiation Biodosimeter (MiRAD)

DESCRIPTION (provided by applicant): The broad long-term goal of this project is to develop an optically based radiation biodosimeter that rapidly (~ 15 minutes) measures changes in serological microRNA (miRNA) biomarkers to predict acute radiation syndrome (ARS). MicroRNAs (miRNAs) are short (18-22 base) non- coding RNA strands that control a host of biological processes through regulation of protein expression. Exposure to radiation has been shown to alter expression of a miRNA panels linked with ARS, thereby establishing that serum could be used as a predictive assay for ARS. To measure changes in these miRNA radiation biomarkers, we will develop a MicroRNA-based Radiation Biodosimeter (MiRAD) system, which combines automated magnetic bead based screening for miRNA targets with Amplified Reflectometric Interference Analysis (ARIA), a patented ChromoLogic technology, for highly sensitive and specific quantification of 100s of miRNA radiation biomarkers in parallel. In preliminary studies, we have demonstrated the novel concept of the device and its ability to accurately measure subfemtomolar concentrations of miRNA in ovarian cancer serum samples, 100x less than current RNA quantification platforms such as RT-PCR. Our preliminary studies using rodent plasma also have identified panel of miRNAs with dose and time dependent response to whole body irradiation (WBI), in a dose range relevant to medical triage in case of a radiological event. The hypotheses we seek to validate under the proposed proof-of-concept study are (1) the miRNA panel identified in a murine model through analysis of plasma can be used to measure WBI dose in a clinical setting; (2) a similar miRNA panel can be used to measure WBI dose in nonhuman primates and humans; (3) the resulting identification of a unique and dose-responsive combination of miRNA markers will result in a rapid, POC blood-based microchip assay for anticipating ARS within the first week of exposure, thereby guiding the allocation of exposed subjects for timely medical intervention.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R43
  • Administering IC
    AI
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    285587
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    855
  • Ed Inst. Type
  • Funding ICs
    NIAID:285587\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    CHROMOLOGIC, LLC
  • Organization Department
  • Organization DUNS
    168312028
  • Organization City
    MONROVIA
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    910164244
  • Organization District
    UNITED STATES